Abstract: A purifying device including a container, at least one cover, a sensing assembly and an ultraviolet source is provided. The container has a containing space, wherein the containing space is adapted to contain a liquid. The cover is adapted to be connected to the container to cover the containing space. The sensing assembly is disposed on the cover, wherein the sensing assembly is adapted to sense a usage state of the cover. The ultraviolet source is disposed on the cover and is adapted to generate an ultraviolet emitted to outside of the cover, wherein the ultraviolet source is turned on or turned off according the usage state of the cover.

Abstract: The present invention provides a pharmaceutical composition for treating a patient suffering from or predisposed to hyperphosphatemia, which contains Mg—Fe—Cl HCln. In one embodiment, the Mg—Fe—Cl HCln is shown in formula (I). The phosphorus uptaking capacity of the pharmaceutical composition is greater than 100 ppm/(g/L). The present invention further provides a method for treating a patient suffering from or predisposed to hyperphosphatemia by using said pharmaceutical composition. The present invention further provides a method of manufacturing the pharmaceutical composition.

Abstract: A door handle for providing a buffering effect has a base, a rotator, an elastic component, a linker, a handle lever, and a damper. The rotator is engaged through the base. The elastic component hooks a limiting rod of the base and the rotator. The linker is disposed around the rotator and has a restricting rib and a pivot rod. The handle lever is inserted into the rotator. A mini buffer of the damper has a cylinder body mounted to the base, and a piston rod. A pivot arm of the damper is disposed around a shaft of the base and rotatably mounted to the piston rod. An extending arm is rotatably mounted to the pivot arm and the pivot rod, respectively. Since damping impact of the buffer effectively retards the restoring process, the strike of the backwardly swinging handle lever is buffered.

Abstract: The present invention provides a pharmaceutical composition for treating a patient suffering from or predisposed to hyperphosphatemia, which contains Mg—Fe—Cl HCln. In one embodiment, the Mg—Fe—Cl HCln is shown in formula (I). The phosphorus uptaking capacity of the pharmaceutical composition is greater than 100 ppm/(g/L). The present invention further provides a method for treating a patient suffering from or predisposed to hyperphosphatemia by using said pharmaceutical composition. The present invention further provides a method of manufacturing the pharmaceutical composition.

Abstract: A purifying device including a container, at least one cover, a sensing assembly and an ultraviolet source is provided. The container has a containing space, wherein the containing space is adapted to contain a liquid. The cover is adapted to be connected to the container to cover the containing space. The sensing assembly is disposed on the cover, wherein the sensing assembly is adapted to sense a usage state of the cover. The ultraviolet source is disposed on the cover and is adapted to generate an ultraviolet emitted to outside of the cover, wherein the ultraviolet source is turned on or turned off according the usage state of the cover.

Abstract: A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.

Abstract: An integrated multi-purpose fastener and allowing summary assembly includes a foldable buckling seat with one end disposed with snap-on device and one end of the snap-on device respectively disposed with movable structures and attachments depending on the function desired.

Abstract: A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.

Abstract: A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.

Abstract: This invention discloses that memantine (MMT) protects dopamine (DA) neurons damage through its potent anti-inflammatory effect by inhibiting microglial over-activation and the protection on DA neuron is a dose-dependent response under an effective amount of lower than 10 mg/kg. This invention also discloses that NADPH oxidase plays a critical role of neuroprotection of MMT and MMT therapy for neurodegeneration diseases and disorder acts in part through an alternative novel mechanism by reducing microglia-associated inflammation. In addition, this invention reveals that MMT is neurotrophic to DA neurons through the release of neurotrophic factors from astroglia.

Abstract: This invention discloses that memantine (MMT) protects dopamine (DA) neurons damage through its potent anti-inflammatory effect by inhibiting microglial over-activation and the protection on DA neuron is a dose-dependent response. This invention also discloses that NADPH oxidase plays a critical role of neuroprotection of MMT and MMT therapy for neurodegeneration diseases acts in part through an alternative novel mechanism by reducing microglia-associated inflammation. In addition, this invention reveals that MMT is neurotrophic to DA neurons through the release of neurotrophic factors from astroglia.

Abstract: A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.

Abstract: A fastener assembly includes a protective cover having an annular part, a cap, and a connecting strip interconnecting elastically the annular part and the cap. A fastening member has a head, a retention flange extending radially and outwardly from a bottom end of the head, an abutting flange that is reduced in diameter and that extends co-axially from the retention flange, and a screw rod that is reduced in diameter and that extends co-axially from the abutting flange. The abutting flange has a thickness greater than that of the annular part of the cover and a diameter smaller than that of a through-hole in the annular part of the cover. The retention flange has a diameter greater than that of the through-hole in the annular part of the cover.

Abstract: A composite medical equipment having the phlegm extraction and mist spraying functions includes a compressor, a phlegm storage container, and a mist sprayer. Thus, the composite medical equipment can provide the phlegm extraction and mist spraying functions simultaneously, thereby reducing cost of the equipment, and thereby facilitating the user using the composite medical equipment.

Abstract: A parasol includes a shank, a rib assembly, a light collecting member, a converting circuit, and a rechargeable battery device. The rib assembly is mounted on an upper portion of the shank, and has a canopy mounted thereon. The light collecting member is mounted on the shank, and is used to receive sunlight and to collect solar energy. The converting circuit is mounted on the shank, is coupled electrically to the light collecting member, and is operable so as to convert the solar energy collected by the light collecting member into electrical energy. The rechargeable battery device is mounted on the shank, is coupled electrically to the converting circuit, and is charged by the electrical energy from the converting circuit.

Abstract: An alloy button including a socket member, and a stud for fastening to the socket member to secure it to the cotton fabric of a piece of garment, the socket member having a cylindrical socket body, an axial mounting hole defined within the socket body, a tapered bottom hole at one end of the socket body for guiding the plain end of the stud into the axial mounting hole, a coupling hole at one end of the axial mounting hole remote from the tapered bottom hole for retaining the plain end of the stud, a tapered flange outwardly raised from one end of the socket body around the coupling hole, and a tapered top hole defined within the tapered flange and covered with an ornamental cap.